Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users.
暂无分享,去创建一个
R. Hogg | J. Montaner | S. Strathdee | E. Wood | T. Kerr | A. Palepu | M. Tyndall | Ruth Zhang | R. Zhang | E. Wood
[1] R. Hogg,et al. Staging for antiretroviral therapy among HIV-infected drug users. , 2004, JAMA.
[2] P. Harrigan,et al. Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy. , 2004, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.
[3] R. Hogg,et al. Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy. , 2003, The Journal of infectious diseases.
[4] R. Hogg,et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[5] Julio S. G. Montaner,et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. , 2001, JAMA.
[6] M. Egger,et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. , 1999, AIDS.
[7] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[8] B. Yip,et al. Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.
[9] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.